impact of additional radiation (RT) and/or androgen deprivation therapy (ADT) on urinary continence, potency and quality of life (QoL) after RP.
INTRODUCTION AND OBJECTIVES: Obesity might negatively affect prostate cancer (PCa) outcomes. However, evidence according to the associations between obesity and metastases-free, as well as PCa-specific survival after radical prostatectomy (RP) is still inconsistent.
METHODS: We relied on PCa patients treated with RP at the Martini-Klinik Prostate Cancer Center between 2004 and 2015. First, multivariable Cox-regression analyses examined the impact of obesity on metastases, PCa-specific death, and death of any cause after RP. Last, in a propensity score matched cohort, Kaplan-Meier analyses assessed metastases-free and overall survival according to body mass index (kg/m2) (BMI) strata (¼30 vs. <25).
RESULTS: Of 13,667 individuals, 1,990 (14.6%) men were obese (BMI ¼30). Median follow-up was 36.4 month (IQR: 13.3-60.8). Obese patients were less likely to exhibit metastases after RP (HR: 0.7, 95% CI: 0.5-0.97, p¼0.03, table 1). Similarly, after propensity score adjustment obesity was associated with increased metastasesfree survival (log rank p¼0.001). Obesity was not significantly associated with PCa-specific death (HR: 1.2; 95% CI: 0.5-2.7; p¼0.8), but with higher risk of death of any cause after RP (HR: 1.7; 95% CI: 1.3-2.3; p¼0.001). Similarly, after propensity score adjustment obesity was associated with decreased overall survival after RP (log rank p¼0.001).
CONCLUSIONS: Obesity was associated with decreased risk of metastases after RP. Improved medical care of diabetes might have contributed to the latter observation. However, further research is needed to unravel the controversially debated association between obesity and PCa.
Source of Funding: None

MP47-05 A SYSTEMATIC REVIEW OF INSTRUMENTAL VARIABLE ANALYSES USING GEOGRAPHIC REGION AS AN INSTRUMENT IN PROSTATE CANCER STUDIES
Emily Vertosick*, Melissa Assel, Andrew Vickers, New York, NY INTRODUCTION AND OBJECTIVES: In many areas of prostate cancer research, such as comparing patient outcomes for radical prostatectomy versus radiotherapy for localized cancer, there are a limited number of randomized trials. Observational studies are used to address such comparisons. Instrumental variables analysis is a methodology to control for confounding in observational studies. Geographic area is being used increasingly as an instrument. We conducted a literature review to determine the properties of geographic area in studies of cancer treatments.
METHODS: We reviewed the literature to identify cancer studies performed in the United States which incorporated instrumental variable analysis with area-wide treatment rate within a geographic region as the instrument. We assessed of the degree of treatment variability between geographic regions, assessed control of confounding afforded by geographic area and compared the results of instrumental variable analysis to those of multivariable methods.
RESULTS: Geographic region as an instrument was relatively common, with 22 eligible studies identified, many of which were published in high-impact journals. Prostate cancer studies made up nearly half of the eligible studies found (10 of 22), including studies of surgery vs. conservative management, primary androgen deprivation vs. conservative management, surgery vs. radiotherapy and open vs. robotic surgery. Geographic region was only weakly associated with the intervention. Most studies reported an absolute difference in treatment rates between high and low use areas of 5% to 20%, with the largest difference being 31%. Absolute differences between high and low use areas reported in prostate studies ranged from 8% to 22%. Four out of seven of these studies reporting on covariate balance Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e629
found at least one covariate to be associated with treatment prevalence. (LNþ) . The ePLND consisted of the external iliac, obturator, internal iliac, presacral and common iliac nodal site up to the ureteric crossing. Specimens from each anatomic site were sent in separate packets. The estimated cancer-specific survival (CSS) and biochemical disease-free survival (bDFS) were calculate by Kaplan-Meier method. Multivariable Cox regression models assessed for prognostic factors of bDFS.
RESULTS: Median follow-up was 48 months (range 14-89); six pts (6%) died of disease at follow-up, while 39 (42%) experienced biochemical failure (PSA > 0.2 ng/ml). Out of 93 patients, 53 pts did not receive adjuvant hormone therapy (AdjHT), 46 pts harboring 2 LNþ. The median number of nodes removed was 22 (range 9-61). The mean and median number of positive nodes was 2.7 and 1 (range: 1-18), respectively. The estimated 5-year CSS was 90%; 5-year bDFS was 45%. Pts with 2 LNþ had significant better 5-year bDFS than those with > 2 LNþ (59% vs 15%; p<0.001). Pts with Gleason score 7 had better 5-year bDFS than those with Gleason score 8-10 (58% vs 36%; p¼0.039). At multivariable Cox regression analysis, presence of more than 2 LNþ was an independent predictor of worse bDFS (p¼0.026; HR 2.2). Among pts who did not receive AdjHT, the estimated 5-year bDFS was 60%, and was significantly higher in pts with 2 LNþ than those with > 2 LNþ (64% vs 34%; p¼0.032).
CONCLUSIONS: Among pts with pathologic node positive disease following radical prostatectomy and ePLND, those with 2 LNþ showed more than 50% bDFS at 5-year follow-up. Good cancer control seems to be achieved also without AdjHT, in pts with limited nodal burden.
Source of Funding: none
MP47-07 SALVAGE ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: ONCOLOGIC AND FUNCTIONAL OUTCOMES FROM TWO HIGH-VOLUME INSTITUTIONS
Gabriel Ogaya-Pinies*, Celebration, Spain; Estefania Linares-Espin os, Madrid, Spain; Rafael S anchez-Salas, Paris, France; Eduardo Hern andez-Cardona, Celebration, FL; Xavier Cathelineau, Paris, France; Vipul Patel, Celebration, FL INTRODUCTION AND OBJECTIVES: Recurrent prostate cancer (PCa) will occur in approximately 25% of cases after primary radiotherapy (RT) and other ablative techniques. While no consensus on the optimal salvage treatment exists, only 3% of these patients will get salvage radical prostatectomy due to the assumed technical challenges of this procedure. We aimed to analyze the perioperative, oncologic and functional outcomes of patients undergoing salvage robotic-assisted radical prostatectomy (sRARP) after primary treatment failure, at two high-volume institutions.
METHODS: Data was prospectively collected and retrospectively reviewed from a combined database of more than 14,800 patients who have undergone RARP. Between 2008-2016, we identified 96 patients who underwent sRARP after RT or ablative techniques. PCa recurrence was biopsy-proven in all cases. We analyzed primary cancer characteristics, surgical data, pathology results, perioperative complications, and oncologic and functional outcomes. RESULTS: Sixty-four patients (66.6%) were treated primarily with RT: 37 with External Beam RT (EBRT), 14 with Brachytherapy and 13 with EBRT þ Brachytherapy. Eighteen patients (18.8%) received cryotherapy as their primary treatment, while 7 patients (7.3%) received HIFU. The remaining seven patients received treatment with either: Cyberknife, electroporation or microwaves. The median surgical time was 128.47 min (98181). Sixteen patients (16.7%) had positive surgical margins, 46 (47.9%) show extraprostatic extension with 22 of them (23%), seminal vesicles invasion (pT3b). Complications were seen in 25 (26%) patients (21 minor and 4 major complications). Anastomotic leak was the most common complication, found in 14 (14.6%) of the cases. No rectal injuries ocurred. Fourteen (15%) patients had a biochemical failure after a median follow-up of 14(IQR 5-24) months. All 96 patients were continent prior to sRARP. Sixty-eight patients (71%) had social continence (0-1pad) and 55 (57%) of them self-reported to be pad free at 12 months, while 13 (13.5%) of them reported to be using 1pad/day. Seventeen(55%) of 31 preoperative potent patients (SHIM score >21), were potent with or without the use of PDE5i at 12 months.
CONCLUSIONS: sRARP is a feasible alternative for PCa recurrence after ablative and radiation therapies. Rectal injuries are uncommon. Technically the procedure is challenging and should be performed by experienced prostate cancer surgeons. Continence and potency recovery is possible but at lower rates than for non-salvage
